225Ac-J591 (Actinium-225 rosopatamab tetraxetan) uses a radioactive particle linked to an antibody that targets PSMA, a protein found on prostate cancer cells, and it is being studied in a phase 1 clinical trial. Unlike more commonly used PSMA treatments that rely on small molecules, this approach uses an antibody, which behaves differently in the body. […]
AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]
211AtPSMA-5 emerges as a promising targeted alpha therapy for metastatic castration-resistant prostate cancer, particularly in patients who have exhausted standard treatments like androgen receptor pathway inhibitors, docetaxel, and cabazitaxel. This approach leverages astatine-211, a cyclotron-produced alpha emitter generated by bombarding abundant bismuth targets with alpha beams. The compound’s design mirrors established PSMA ligands such as […]
A new study from Wuhan University and the Renmin Hospital of Wuhan University has reported a promising preclinical strategy for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC). The work was published online in Angewandte Chemie International Edition, one of the leading international journals in chemistry. The study describes a new nano-PROTAC platform designed to […]
Nature reports the results of the HC‑1119‑04 trial, a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of deutenzalutamide (HC‑1119) in metastatic castration‑resistant prostate cancer (mCRPC) after treatment with abiraterone and docetaxel. The trial was conducted in China and enrolled 417 patients, with 276 randomized to deutenzalutamide 80 mg once daily and 141 to placebo. All […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Please bear with me for one more week. Next Friday the annual AACR 2026 meeting begins, and I should finally have access to the clinical trial data that will be presented. It will be a very busy weekend! For […]
In a detailed review of two large clinical trials called ARCHES and PROSPER, doctors found that some patients experienced cancer growth visible on scans (known as radiographic progression) without seeing the usual rise in PSA blood levels, a key marker doctors often track. This mismatch highlights why regular imaging tests might be just as crucial […]
Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]
A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]
EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]